Bausch + Lomb Corporation Registered Shs Reg S News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

30.10.24	Bausch + Lomb Turns To Q3 Profit; Raises Full-year Revenue Outlook (RTTNews)
14.10.24	Bausch + Lomb : FDA Approves EnVista Envy Full Range Of Vision Intraocular Lens (RTTNews)
18.09.24	SLNO Skyrockets 800%, BWAY Blasts Past 400% - Were You On Board? (RTTNews)
21.02.24	Bausch + Lomb Q4 Adj. Net Income Rises (RTTNews)
08.01.24	Bausch + Lomb Receives FDA Approval For TENEO For Vision Correction Surgery (RTTNews)
01.11.23	Bausch + Lomb Q3 Adj. Profit Declines; Revenues Up 8% On Constant Currency Basis (RTTNews)
29.09.23	Novartis Completes Divestment Of 'front Of Eye' Ophthalmology Assets To Bausch + Lomb (RTTNews)
12.09.23	Bausch + Lomb Launches MIEBO To Treat Dry Eye Disease (RTTNews)
11.09.23	Bausch + Lomb Unit Launches Offering Of $1.4 Bln Of New Senior Secured Notes (RTTNews)
30.06.23	Bausch + Lomb To Buy XIIDRA Eye Drop From Novartis In Up To $2.5 Bln Deal; Stock Up In Premarket (RTTNews)
15.02.23	Bausch + Lomb Appoints Brent Saunders As CEO (RTTNews)
22.12.22	Bausch + Lomb Amends CEO Separation Agreement (PR Newswire)
13.12.22	Bausch + Lomb Receives 510(k) Clearance from FDA for Biotrue® Hydration Boost Contact Lens Rehydrating Drops (PR Newswire)
12.12.22	Bausch + Lomb's ONE by ONE and Biotrue® Eye Care Recycling Programs Win Gold for Most Environmentally Friendly Service of the Year from Best in Biz Awards (PR Newswire)
29.11.22	Bausch + Lomb's Biotrue® Hydration Plus Multi-Purpose Solution Receives Product of the Year Award from Business Intelligence Group's 2022 BIG Awards for Business (PR Newswire)
15.11.22	Bausch + Lomb Reports More Than 58 Million Units of Contact Lens, Lens Care and Eye Care Materials Collected Through ONE By ONE and Biotrue® Eye Care Recycling Programs (PR Newswire)
07.11.22	Bausch + Lomb Announces Participation at the 5th Annual Evercore ISI HealthCONx Conference (PR Newswire)
02.11.22	Bausch + Lomb Announces Third-Quarter 2022 Results (PR Newswire)
01.11.22	Bausch + Lomb #LUMIFYEyeDance Challenge Wins 2022 Public Relations and Marketing Excellence Award for External Campaign of the Year from Business Intelligence Group (PR Newswire)
24.10.22	Bausch + Lomb Introduces Project Watson™ Health Care Products for Dogs (PR Newswire)
18.10.22	Bausch + Lomb Announces Presentation of Scientific Data and Analyses Evaluating Biotrue® Hydration Plus Multi-Purpose Solution at American Academy of Optometry Annual Meeting (PR Newswire)
04.10.22	Bausch + Lomb Will Release Third-Quarter 2022 Financial Results on November 2 (PR Newswire)
03.10.22	Bausch + Lomb Introduces Enhanced Ocuvite® Adult 50+ Eye Vitamin Formulation With Vitamin D (PR Newswire)
27.09.22	Bausch + Lomb Will Present Scientific Data and Analyses During World Cornea Congress (PR Newswire)
26.09.22	Bausch + Lomb Will Present New Scientific Data and Analyses During the American Academy of Ophthalmology Annual Meeting (PR Newswire)
21.09.22	Bausch + Lomb Announces Webinar for Eye Care Professionals on New AREDS2 Study Findings (PR Newswire)
13.09.22	First Annual Bausch + Lomb Sponsored Visionary Report Spotlights Nation's 'Blind Spots' on Age-related Macular Degeneration, a Leading Cause of Vision Loss for People 50+ (PR Newswire)
06.09.22	FDA Accepts Bausch + Lomb/Novaliq's New Drug Application For NOV03; Decision Due On June 28 (RTTNews)
06.09.22	Bausch + Lomb and Novaliq Announce U.S. FDA Filing Acceptance for Investigational Treatment NOV03 (Perfluorohexyloctane) (PR Newswire)
01.09.22	Bausch + Lomb Named Exclusive Global Distributor of Alfa Instruments s.r.l. Intraocular Dyes (PR Newswire)
29.08.22	Bausch + Lomb Announces Participation at Upcoming Investor Conferences (PR Newswire)
04.08.22	Bausch + Lomb Announces Second-Quarter 2022 Results (PR Newswire)
28.07.22	Bausch + Lomb Launches the #LUMIFYEyeDance Challenge on TikTok (PR Newswire)
28.07.22	Bausch + Lomb and Sanoculis Announce Strategic Agreements Designed to Address Unmet Needs in Glaucoma (PR Newswire)
26.07.22	Bausch + Lomb Enrolls First Patient in LASIK Clinical Trial Evaluating Use of Technolas® TENEO™ Excimer Laser* for Vision Correction Surgery for Hyperopia with Astigmatism (PR Newswire)
25.07.22	Bausch + Lomb Will Release Second-Quarter 2022 Financial Results on August 4 (PR Newswire)
20.07.22	Bausch + Lomb Board Chairman Joseph Papa Steps Down (RTTNews)
20.07.22	Bausch + Lomb Provides Leadership Update (PR Newswire)
07.07.22	Bausch + Lomb and Novaliq Announce Submission of New Drug Application for Investigational Treatment NOV03 (Perfluorohexyloctane) (PR Newswire)
06.07.22	Bausch + Lomb Announces Scientific Data on XIPERE® (Triamcinolone Acetonide Injectable Suspension) to be Presented During the American Society of Retina Specialists Annual Scientific Meeting (PR Newswire)
23.06.22	Bausch + Lomb Announces Brett Icahn and Gary Hu Have Been Appointed to its Board of Directors (PR Newswire)
13.06.22	Bausch + Lomb Announces the U.S. Launch of Revive™ Custom Soft Contact Lenses (PR Newswire)
08.06.22	Bausch + Lomb Announces First-Quarter 2022 Results and Provides 2022 Guidance (PR Newswire)
06.06.22	Bausch + Lomb Announces Scientific Data on Latest Biotrue® Products to be Presented at American Optometric Association's Optometry's Meeting (PR Newswire)
02.06.22	New Social Media Campaign From Bausch + Lomb Aims to Raise Awareness that Cataracts Don't Wait (PR Newswire)
02.06.22	Bausch + Lomb Announces the U.S. Launch of Biotrue® Hydration Plus Multi-Purpose Solution (PR Newswire)
25.05.22	Bausch + Lomb Will Release First-Quarter 2022 Financial Results on June 8 (PR Newswire)
24.05.22	Bausch + Lomb Receives Health Canada Approval of LUMIFY® Redness Reliever Eye Drops (PR Newswire)
17.05.22	Bausch + Lomb Corporation Files Financial Statements for the First Quarter of 2022 (PR Newswire)
13.05.22	Bausch + Lomb Announces Participation at the RBC Capital Markets Global Healthcare Conference (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Logitech Intl	71.14	1.54 %	K V
UBS Group	28.08	1.48 %	K V
Swiss Re	130.05	1.05 %	K V
Part Grp Hldg	1’266.00	0.96 %	K V
ABB	49.48	0.94 %	K V
Geberit	525.20	0.27 %	K V
Alcon	78.04	0.05 %	K V
Givaudan	3’868.00	-0.31 %	K V
CieFinRichemont	121.20	-0.57 %	K V
Sonova Hldg	301.00	-0.99 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Bausch + Lomb Corporation Registered Shs Reg S

Aktien Top/Flop

Meistgelesene Nachrichten